` ENZC (Enzolytics Inc) vs S&P 500 Comparison - Alpha Spread

ENZC
vs
S&P 500

Over the past 12 months, ENZC has underperformed S&P 500, delivering a return of -70% compared to the S&P 500's +14% growth.

Stocks Performance
ENZC vs S&P 500

Loading
ENZC
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
ENZC vs S&P 500

Loading
ENZC
S&P 500
Difference
www.alphaspread.com

Performance By Year
ENZC vs S&P 500

Loading
ENZC
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Enzolytics Inc vs Peers

S&P 500
ENZC
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Enzolytics Inc
Glance View

Market Cap
1.4m USD
Industry
Biotechnology

Enzolytics, Inc. is a biotechnology company, which engages in the development and commercialization of drugs for infectious disease treatments. The company is headquartered in Plano, Texas. The company went IPO on 2008-12-29. The firm is engaged in the commercialization of its proteins for the treatment of debilitating infectious diseases. The firm is focused in developing monoclonal antibody therapy and treating infectious diseases. The company has anti-HIV therapeutics and a methodology for producing fully human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy. The firm has clinically tested anti-HIV therapeutics. The firm has developed a cell line that produces fully human monoclonal antibodies that target and neutralizes the HIV virus. The firm has also created human cell lines that produce human antibodies against other infectious diseases, including rabies, influenza, tetanus, and diphtheria. The firm is testing these antibodies to prepare them for use as therapies against these diseases.

ENZC Intrinsic Value
Not Available
Back to Top